180 related articles for article (PubMed ID: 29112594)
1. Sexual activity and vaginal symptoms in the postintervention phase of the Women's Health Initiative Hormone Therapy Trials.
Gass M; Larson J; Cochrane B; Manson JE; Lane D; Barnabei V; Ockene J; Stefanick ML; Mouton C
Menopause; 2018 Mar; 25(3):252-264. PubMed ID: 29112594
[TBL] [Abstract][Full Text] [Related]
2. Patterns and predictors of sexual activity among women in the Hormone Therapy trials of the Women's Health Initiative.
Gass ML; Cochrane BB; Larson JC; Manson JE; Barnabei VM; Brzyski RG; Lane DS; LaValleur J; Ockene JK; Mouton CP; Barad DH
Menopause; 2011 Nov; 18(11):1160-71. PubMed ID: 21983008
[TBL] [Abstract][Full Text] [Related]
3. Coronary heart disease events in the Women's Health Initiative hormone trials: effect modification by metabolic syndrome: a nested case-control study within the Women's Health Initiative randomized clinical trials.
Wild RA; Wu C; Curb JD; Martin LW; Phillips L; Stefanick M; Trevisan M; Manson JE
Menopause; 2013 Mar; 20(3):254-60. PubMed ID: 23435021
[TBL] [Abstract][Full Text] [Related]
4. Menopausal hormone therapy and risk of epithelial ovarian cancer.
Rossing MA; Cushing-Haugen KL; Wicklund KG; Doherty JA; Weiss NS
Cancer Epidemiol Biomarkers Prev; 2007 Dec; 16(12):2548-56. PubMed ID: 18086757
[TBL] [Abstract][Full Text] [Related]
5. Effects of Oral vs Transdermal Estrogen Therapy on Sexual Function in Early Postmenopause: Ancillary Study of the Kronos Early Estrogen Prevention Study (KEEPS).
Taylor HS; Tal A; Pal L; Li F; Black DM; Brinton EA; Budoff MJ; Cedars MI; Du W; Hodis HN; Lobo RA; Manson JE; Merriam GR; Miller VM; Naftolin F; Neal-Perry G; Santoro NF; Harman SM
JAMA Intern Med; 2017 Oct; 177(10):1471-1479. PubMed ID: 28846767
[TBL] [Abstract][Full Text] [Related]
6. Vaginal estrogen use and effects on quality of life and urogenital morbidity in postmenopausal women after publication of the Women's Health Initiative in New York City.
Setty P; Rekedal L; Warren MP
Menopause; 2016 Jan; 23(1):7-10. PubMed ID: 26263282
[TBL] [Abstract][Full Text] [Related]
7. Symptom experience after discontinuing use of estrogen plus progestin.
Ockene JK; Barad DH; Cochrane BB; Larson JC; Gass M; Wassertheil-Smoller S; Manson JE; Barnabei VM; Lane DS; Brzyski RG; Rosal MC; Wylie-Rosett J; Hays J
JAMA; 2005 Jul; 294(2):183-93. PubMed ID: 16014592
[TBL] [Abstract][Full Text] [Related]
8. A randomized study of low-dose conjugated estrogens on sexual function and quality of life in postmenopausal women.
Gast MJ; Freedman MA; Vieweg AJ; De Melo NR; Girão MJ; Zinaman MJ;
Menopause; 2009; 16(2):247-56. PubMed ID: 19034054
[TBL] [Abstract][Full Text] [Related]
9. Changes of menopausal hormone therapy use pattern since 2000: results of the Berlin Spandau Longitudinal Health Study.
Du Y; Scheidt-Nave C; Schaffrath Rosario A; Ellert U; Dören M; Knopf H
Climacteric; 2009 Aug; 12(4):329-40. PubMed ID: 19437194
[TBL] [Abstract][Full Text] [Related]
10. Menopausal hormone therapy and women's health: An umbrella review.
Zhang GQ; Chen JL; Luo Y; Mathur MB; Anagnostis P; Nurmatov U; Talibov M; Zhang J; Hawrylowicz CM; Lumsden MA; Critchley H; Sheikh A; Lundbäck B; Lässer C; Kankaanranta H; Lee SH; Nwaru BI
PLoS Med; 2021 Aug; 18(8):e1003731. PubMed ID: 34339416
[TBL] [Abstract][Full Text] [Related]
11. Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study.
Chlebowski RT; Manson JE; Anderson GL; Cauley JA; Aragaki AK; Stefanick ML; Lane DS; Johnson KC; Wactawski-Wende J; Chen C; Qi L; Yasmeen S; Newcomb PA; Prentice RL
J Natl Cancer Inst; 2013 Apr; 105(8):526-35. PubMed ID: 23543779
[TBL] [Abstract][Full Text] [Related]
12. Use of postmenopausal hormone therapies and risk of histology- and hormone receptor-defined breast cancer: results from a 15-year prospective analysis of NIH-AARP cohort.
Wang SM; Pfeiffer RM; Gierach GL; Falk RT
Breast Cancer Res; 2020 Nov; 22(1):129. PubMed ID: 33239054
[TBL] [Abstract][Full Text] [Related]
13. Attitudes of women who are currently using or recently stopped estrogen replacement therapy with or without progestins: results of the AWARE survey.
Sawka AM; Huh A; Dolovich L; Papaioannou A; Eva K; Thabane L; Gafni A; Cullimore A; Macdougall M; Steiner M; Adachi JD
J Obstet Gynaecol Can; 2004 Nov; 26(11):967-73. PubMed ID: 15560859
[TBL] [Abstract][Full Text] [Related]
14. The Women's Health Initiative trials of menopausal hormone therapy: lessons learned.
Manson JE; Bassuk SS; Kaunitz AM; Pinkerton JV
Menopause; 2020 Aug; 27(8):918-928. PubMed ID: 32345788
[TBL] [Abstract][Full Text] [Related]
15. Health related quality of life after combined hormone replacement therapy: randomised controlled trial.
Welton AJ; Vickers MR; Kim J; Ford D; Lawton BA; MacLennan AH; Meredith SK; Martin J; Meade TW;
BMJ; 2008 Aug; 337():a1190. PubMed ID: 18719013
[TBL] [Abstract][Full Text] [Related]
16. The effects of postmenopausal hormone therapy on serum estrogen, progesterone, and sex hormone-binding globulin levels in healthy postmenopausal women.
Edlefsen KL; Jackson RD; Prentice RL; Janssen I; Rajkovic A; O'Sullivan MJ; Anderson G
Menopause; 2010; 17(3):622-9. PubMed ID: 20215977
[TBL] [Abstract][Full Text] [Related]
17. No Increase in Fractures After Stopping Hormone Therapy: Results From the Women's Health Initiative.
Watts NB; Cauley JA; Jackson RD; LaCroix AZ; Lewis CE; Manson JE; Neuner JM; Phillips LS; Stefanick ML; Wactawski-Wende J; Crandall C;
J Clin Endocrinol Metab; 2017 Jan; 102(1):302-308. PubMed ID: 27820659
[TBL] [Abstract][Full Text] [Related]
18. The 2017 hormone therapy position statement of The North American Menopause Society.
Menopause; 2018 Nov; 25(11):1362-1387. PubMed ID: 30358733
[TBL] [Abstract][Full Text] [Related]
19. Cardiac Death Risk in Relation to the Age at Initiation or the Progestin Component of Hormone Therapies.
Savolainen-Peltonen H; Tuomikoski P; Korhonen P; Hoti F; Vattulainen P; Gissler M; Ylikorkala O; Mikkola TS
J Clin Endocrinol Metab; 2016 Jul; 101(7):2794-801. PubMed ID: 27172432
[TBL] [Abstract][Full Text] [Related]
20. The 2017 hormone therapy position statement of The North American Menopause Society.
The NAMS 2017 Hormone Therapy Position Statement Advisory Panel
Menopause; 2017 Jul; 24(7):728-753. PubMed ID: 28650869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
